PPD expands lab space, staffing at Ireland facility

PPD has expanded its GMP lab operations in Athlone, Ireland, by another 4,300 square feet to conduct analytical testing of biopharma products and inhalation devices.

The CRO’s Athlone facility--which now stands at 41,500 square feet--has been providing services through the life cycle of pharmaceutical product development, including analytical and stability testing, method development and validation, regulatory services, product licensing and marketed product support. It's licensed by Ireland's Health Products Regulatory Authority.

PPD's expansion is part of the North Carolina-based company’s recent effort to bolster its lab capacity. This summer, it completed its acquisition of Evidera, a provider of evidence-based solutions in examining effectiveness of new drugs.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

The Athlone lab opened in 2010 and will employ about 200 people after completion of the latest expansion. PPD also offers the same set of services in the U.S. through another GMP lab in Middleton, WI. The two locations together house more than 1,300 employees.

As the company’s website shows, it employs about 18,500 people globally after the Evidera buy. Besides the above two locations, it also operates labs of different functions in Shanghai, Brussels, Highland Heights, KY, and Richmond, VA.

Suggested Articles

Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Studies for new drugs are still suffering.

Tempus fugit: And time especially flies when it comes clinical trials. Covance is teaming up with the suitably named Tempus to clip its wings.

PPD has raised its quarterly guidance after weathering the COVID-19 storm and is immediately making a secondary offering of 38 million shares.